Lilium lancifolium extract powder,
does it really help with Improvement of joint discomfort and function?
research showsA trial of 100 participants taking HY-LL at 1 g/day for 12 weeks found small improvements over placebo in VAS and K-WOMAC pain and function. It used a per-protocol analysis, was a single-product study in which 9 of 10 authors were affiliated with the ingredient supplier hy, and found no between-group difference in objective biomarkers.
ads claimIndividual recognition or a product launch does not establish equivalent efficacy for Lilium foods or extracts with different specifications.
Useful facts when choosing a product
- The HY-LL dose in the clinical trial was 1 g/day.
- hy supplied the study material and 9 of 10 authors were affiliated with hy.
- Official hy material confirms a joint-health product using the ingredient, but the sales format is not independent efficacy evidence.
What the research actually shows
The key evidence is one double-blind randomized placebo-controlled trial of 100 randomized participants using HY-LL at 1 g/day for 12 weeks.
Why this is classified as C (48)
A C cap applies because the evidence is one manufacturer-linked proprietary-ingredient RCT using subjective VAS and WOMAC endpoints.
Counterpoint. The positive trial is not dismissed, but objective outcomes and independent replication are needed.
Rejudgment record. Reassessment (cross-check reflected) — C cap for a manufacturer-linked proprietary ingredient and subjective joint endpoints
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improvement of joint pain and discomfort | C | Single-trial signal in VAS and WOMAC pain |
| Improvement of joint function | C | Small between-group difference in WOMAC function |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Jeon et al. (2024), Life (Basel) | Randomized double-blind placebo-controlled trial, 12 weeks | 100 | Reported no external funding; hy supplied the study product and many authors were hy employees | VAS, K-WOMAC, and joint-related blood biomarkers | VAS and K-WOMAC total, pain, and function showed significant between-group differences; biomarkers did not | Moderate-low |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-16).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-16 · Corrections: none
Cite this verdict
[Chamgap] Does Lilium lancifolium extract improve joint discomfort and function? — Evidence Grade C·48. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/joint-bone/lilium-lancifolium-extract/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.